The challenge of invasive fungal infection

Chemotherapy

Volumn 45, Issue , 1999, Pages 1-14

  de Pauw, B E ^a   Meunier, F ^a  

^a EORTC DATA CENTER   (Belgium)

Author keywords

Amphotericin B; Aspergillosis; Candidiasis; Fluconazole; Fungus; Immunocompromised host; Itraconazole; Lipid formulation

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCYTOSINE; IMIDAZOLE DERIVATIVE; TRIAZOLE DERIVATIVE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; ASPERGILLOSIS; CANCER PATIENT; CANDIDIASIS; CRITICAL ILLNESS; INFECTIOUS COMPLICATION; INTENSIVE CARE; LEUKEMIA; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; CRYPTOCOCCOSIS; DEOXYCHOLIC ACID; DRUG COMBINATIONS; FLUCONAZOLE; FLUCYTOSINE; FUNGEMIA; HISTOPLASMOSIS; HUMANS; IMMUNOCOMPROMISED HOST; MYCOSES; ZYGOMYCOSIS;

EID: 0033038241     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000048465     Document Type: Article

References (66)

1. Bodey G, Bueltmann B, Duguid W, et al: Fungal infections in cancer patients: An international autopsy survey. Eur J Microbiol Infect Dis 1992;11:99-109.
2. Fisher-Hoch SP, Hutwagner L: Opportunistic candidiasis: An epidemic of the 1980s. Clin Infect Dis 1995;21:897-904.
3. Dismukes WE: Cryptococcal meningitis in patients with AIDS. J Infect Dis 1988;157:624-628.
4. Paya CV: Fungal infections in solidorgan transplantation. Clin Infect Dis 1993;16:677-688.
5. Selik RM, Starcher ET, Curran JW: Opportunistic diseases reported in AIDS patients: frequencies associations and trends. AIDS 1987; 1:175-182.
6. Edwards JE, Bodey GP, Bowden RA, et al: International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin Infect Dis 1997;25:43-59.
7. Anaissie EJ, Darouiche RO, Abi-Said D, et al: Management of invasive candidal infections: Results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and a review of the literature. Clin Infect Dis 1996;23: 964-972.
8. de Pauw BE, Meis JFGM: Progress in fighting systemic fungal infections in haematological neoplasia. Supp Care Cancer 1998;6:31-38.
9. de Pauw BE: Practical modalities for prevention of fungal infections in cancer patients. Eur J Clin Microbiol Infect Dis 1997;16:32-41.
10. Armstrong D: Treatment of opportunistic fungal infections. Clin Infect Dis 1993;16:1-9.
11. Caillot D, Casanovas O, Bernard A, et al: Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997; 15: 139-147.
12. Verweij PE, Stynen D, Rijs AJMM, de Pauw BE, Hoogkamp-Korstanje JA, Meis JF: Sandwich enzyme-linked immunosorbent assay compared with Pastorex latex agglutination test for diagnosing invasive aspergillosis in immunocompromised patients. J Clin Microbiol 1995;33: 1912-1914.
13. Bretagne S, Costa J-M, Bart-Dela-besse E, Dhédin N, Rieux C, Cordonnier C: Comparison of serum galactomannan antigen detection and competitive polymerase chain reaction for diagnosing invasive aspergillosis. Clin Infect Dis 1998;26: 1407-1412.
14. Lecciones JA, Lee JW, Navarro EE, et al: Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes. Clin Infect Dis 1992;14:875-883.
15. Horn R, Wong B, Kiehn TE, Armstrong D: Fungemia in a cancer hospital: Changing frequency, earlier onset, and results of therapy. Rev Infect Dis 1985;7:646-655.
16. Meunier F, Aoun M, Bitar N: Can-didemia in immunocompromised patients. Clin Infect Dis 1992; 14 (suppl 1):S120-S125.
17. Fraser VJ, Jones M, Dunkel J, Stor-fer S, Medoff G, Gunagan WC: Can-didemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992;15:414-421.
18. Viscoli C, Girmenia C, Marinus A, Martino P, Meunier F, the Invasive Fungal Infection Group (IFIG) of the European Organisation for Research and Treatment of Cancer (EORTC). A surveillance study of fungemia in cancer patients. Clin Infect Dis 1999, in press.
19. Edwards JE, Lehrer RI, Stiehm ER, Fischer TJ, Young LS: Severe candidal infections. Clinical perspective, immune defense mechanisms, and current concepts of therapy. Ann Intern Med 1978;89:91-106.
20. Wey SB, Mori M, Pfaller MA, Wool-son RF, Wenzel RP: Hospital-Acquired Candidemia. The Attributable Mortality and Excess Length of Stay. Arch Intern Med 1988; 148: 2642-2645.
21. Anaissie EJ, Rex JH, Uzun O, Varti-varian S: Predictors of adverse outcome in cancer patients with candi-demia. Am J Med 1998; 104:238245.
22. Haron E, Feld R, Tuffnell P, Patterson B, Hasselback B, Matlow A: Hepatic candidiasis: An increasing problem in immunocompromised patients. Am J Med 1987;83:17-26.
23. Meunier F: Candidosis. Eur J Clin Microbiol Infect Dis 1989;8:438-447.
24. Masur H, Rosen PP, Armstrong D: Pulmonary disease caused by Candida species. Am J Med 1977;63: 914-925.
25. Aisner J, Sickles E, Schimpff S, Young VM, Greene WH: Torulopsis glabrata pneumonitis in patients with cancer. J Am Med Association 1974;230:584-585.
26. Calandra T, Bille J, Schneider R, Mosimann F, Francioli P: Clinical significance of Candida isolated from peritoneum in surgical patients. Lancet 1989;ii: 1437-1439.
27. Lipton SA, Hickey WF, Morris JH, Loscalzo J: Candidal infection in the central nervous system. Am J Med 1984;76:101-108.
28. Menezes A, Sigesmund DA, Demajo WA, Devenyi RG: Mortality of hospitalized patients with Candida endophthalmitis. Arch Intern Med 1994;154:2093-2097.
29. Gathe JC, Harris RL, Garland B, Bradshaw MW, Williams TW: Candida osteomyelitis. Report of five cases and review of the literature. Am J Med 1987;82:927-937.
30. Zeluff BJ: Fungal pneumonia in transplant recipients. Semin Respir Infect 1990;5:80-89.
31. Wald A, Leisenring W, van Burik J-A, Bowden RA: Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997;175:1459-1466.
32. Denning DW, Stevens DA: Antifungal and Surgical Treatment of Invasive Aspergillosis: Review of 2,121 Published Cases. Rev Infect Dis 1990;12:1147-1201.
33. Samonis G, Bafaloukos D: Fungal infections in cancer patients: An escalating problem. In Vivo 1992;6: 183-194.
34. Anaissie E, Bodey GP, Kanterjian H, et al: New spectrum of fungal infections in patients with cancer. Rev Infect Dis 1989;2:369-378.
35. Lyman CA, Walsh TJ: Systemically administered antifungal agents. Drugs 1992;44:9-35.
36. Wong-Beringer A, Jacobs RA, Guglielmo BJ: Lipid formulation of amphotericin B: Clinical efficacy and toxicities. Clin Infect Dis 1998; 27:603-618.
37. White MH, Bowden RA, Sandler ES, et al: Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998;27:296-302.
38. Walsh TJ, Finberg RW, Arndt C, et al for the National Institute of Allergy and Infectious Diseases Mycoses Study Group: Liposomal amphotericin B for empirical therapy in patients with persisting fever and neutropenia. N Engl J Med 1999;340: 764-771.
39. Prentice HG, Hahn IM, Herbrecht R, et al: A randomised comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997;98:711-718.
40. White MH, Anaissie EJ, Kusne S, et al: Amphotericin B colloidal disperions vs. amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis 1997;24:635-642.
41. Noskin GA, Pietrelli L, Coffey G, Gurwith M, Liang L-J: Amphotericin B colloidal dispersion for treatment of candidemia in immunocompromised patients. Clin Infect Dis 1998;26:461-467.
42. Leenders ACAP, Daenen S, Jansen RLH, et al: Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 1998;103: 205-212.
43. Ellis M, Spence D, de Pauw B, et al: An EORTC multicenter randomised trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 1998;27:1406-1412.
44. Meunier F, Prentice HG, Ringden O: Liposomal amphotericin B: Safety data from a phase II/III clinical trial with Ambisome. J Antimicrob Chemother 1991;28(suppl B):83-91.
45. Oppenheim BA, Herbrecht R, Kusne S: The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin Infect Dis 1995;21: 1145-1153.
46. Kline S, Larsen TA, Fieber L, Fish-bach R, et al: Limited toxicity of prolonged therapy with high doses of amphotericin B lipid complex. Clin Infect Dis 1995;21:1154-1158.
47. Walsh TJ, Hiemenz JW, Seibel NL, et al: Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998;26: 1383-1396.
48. Ng TTC, Denning DW: Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data. Arch Int Med 1995;155:1093-1098.
49. Lister J: Amphotericin B lipid complex (Abelcet®) in the treatment of invasive mycoses: the North American experience. Eur J Haematol 1996;56(suppl 57):18-23.
50. Mehta J, Kelsey S, Chu P, et al: Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematologic malignancies. Bone Marrow Transpl 1997;20: 39-43.
51. Bowden RA, Cays M, Gooley T, Mamelok RD, van Burik J-A: Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant. J Infect Dis 1996;173: 1208-1215.
52. Anaissie EJ, Mattiuzzi N, Miller CB, et al: Treatment of invasive fungal infections in renally impaired patients with amphotericin B colloidal dispersion. Antimicrob Agents Chemother 1998;42:606-611.
53. Schöffski P, Freund M, Wunder R, et al: Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: Randomised study. Br J Med 1998;317:379-384.
54. Sheehan DJ, Hitchcock CA, Sibley CM: Current and emerging azole antifungal agents. Clin Microbiol Rev 1999;12:40-79.
55. Meunier F: Management of candi-demia. N Engl J Med 1994;331: 1371-1372.
56. Rex J, Bennett J, Sugar A, et al: A randomised trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994;331:1325-1330.
57. Stevens DA, Lee JY: Analysis of compassionate use of itraconazole therapy for invasive aspergillosis by the NIAID Mycosis Study Group criteria. Arch Int Med 1997; 157: 1857-1862.
58. Phillips P, De Beule K, Frechette G, et al: A double-blind comparison of itraconazole oral solution and fluconazole capsules for the treatment of oropharyngeal candidiasis in patients with AIDS. Clin Infect Dis 1998;26:1368-1373.
59. Wingard JR, Merz WG, Rinaldi MG, Miller CB, Karp JE, Saral R: Association of Torulopsis glabrata infections in neutropenic bone marrow transplantation patients. An-timicrob Agents Chemother 1993; 37:1847-1849.
60. Rex J, Rinaldi M, Pfaller M: Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995;39:1-8.
61. Como JA, Dismukes WE: Oral azole drugs as systemic antifungal therapy. New Engl J Med 1994;330:263-272.
62. British Society for Antimicrobial Chemotherapy Working Party: Management of deep Candida infection in surgical and intensive care unit patients. Intensive Care Med 1994;20:522-528.
63. Rex JH, Bennett JE, Sugar AM, et al: Intravascular catheter exchange and duration of candidemia. Clin Infect Dis 1995;21:994-996.
64. Bennet J, Dismukes W, Duma R, et al: A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med 1979;301: 126-131.
65. Saag MS, Powderly WG, Cloud GA, et al: Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med 1992;326: 83-89.
66. Meyer RD: Current role of therapy with amphotericin B. Clin Infect Dis 1992;14(suppl 1):S154-S160.